143 related articles for article (PubMed ID: 25386814)
1. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Future Oncol; 2014 Oct; 10(12):1981-92. PubMed ID: 25386814
[TBL] [Abstract][Full Text] [Related]
2. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
3. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
4. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Gyawali B; Shimokata T; Ando M; Honda K; Ando Y
Ann Oncol; 2017 Feb; 28(2):246-253. PubMed ID: 27771613
[TBL] [Abstract][Full Text] [Related]
5. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
[TBL] [Abstract][Full Text] [Related]
6. Risk of treatment-related mortality with sorafenib in patients with cancer.
Zhang XJ; Zhang TY; Yu FF; Wei X; Li YS; Xu F; Wei LX; He J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6681-6. PubMed ID: 24377588
[TBL] [Abstract][Full Text] [Related]
7. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
Yang X; Pan X; Cheng X; Cheng Y; Kuang Y
Int J Clin Pharm; 2015 Dec; 37(6):1047-56. PubMed ID: 26173936
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Li Y; Li S; Zhu Y; Liang X; Meng H; Chen J; Zhang D; Guo H; Shi B
J Clin Hypertens (Greenwich); 2014 Mar; 16(3):177-85. PubMed ID: 24621095
[TBL] [Abstract][Full Text] [Related]
10. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
11. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
Abdel-Rahman O; Lamarca A
Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):75-83. PubMed ID: 27882800
[TBL] [Abstract][Full Text] [Related]
12. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
13. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
[TBL] [Abstract][Full Text] [Related]
15. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Chu D; Lacouture ME; Fillos T; Wu S
Acta Oncol; 2008; 47(2):176-86. PubMed ID: 18210295
[TBL] [Abstract][Full Text] [Related]
16. The adverse effects of sorafenib in patients with advanced cancers.
Li Y; Gao ZH; Qu XJ
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):216-21. PubMed ID: 25495944
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of dermatological toxicities associated with sorafenib.
Zhang L; Zhou Q; Ma L; Wu Z; Wang Y
Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
[TBL] [Abstract][Full Text] [Related]
18. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
19. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Shin SY; Lee YJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):837-46. PubMed ID: 24075093
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
